Replies to post #142968 on Avid Bioservices Inc (CDMO)

[biopharm]

CTO 10.26 10.27 relates to Stason Pharmaceuticals

Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. We have R&D and manufacturing facilities in California, USA, and Taiwan. Additional R&D facilities are located in Massachusetts, USA, and China. Our licensing offices are located in California, USA and Tokyo, Japan.

http://www.stasonpharma.com/company/
------------------------------------------------------------------

So we have the manufacturing... hiring... tech transfer all going on and since the agreements are already in place with Stason, these CTO's look to be keeping the pricing and agreements between the two companies under lock and key for a few years and who knows, may get extended again for protect Peregrine if they are going to need another manufacturing/production facility to partner with ... OR .... if for some reason anything happens with the Stason deal in general, others will not know how much leverage Peregrine has had in their current agreements.

------------------------------------------------------------------

From the Stason website.... and I'd say its very possible they are referring to the Peregrine agreement:

"In 2008, Stason launched the Brand Division when we acquired exclusive development and commercialization rights to two early phase novel proprietary compounds in the area of oncology. This division within Stason is focused on New Chemical Entities (NCEs) which provide for unmet medical needs. We are dedicated to building our branded product portfolio through internal development, as well as licensing and acquisition. Through our worldwide strategic alliances, these products will be distributed and/or licensed on a worldwide, or territory specific basis."

http://www.stasonpharma.com/divisions/brand/

[EYEBUYSTOX]

Re: CTO

LOL...they don't want the $hiddy terms of the Stason deal made public as they're trying to negotiate.